IBDEI03Q ; ; 06-AUG-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 06, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,4641,1,4,0)
 ;;=4^OSTEOMALACIA NOS
 ;;^UTILITY(U,$J,358.3,4641,1,5,0)
 ;;=5^268.2
 ;;^UTILITY(U,$J,358.3,4641,2)
 ;;=^87103
 ;;^UTILITY(U,$J,358.3,4642,0)
 ;;=756.52^^45^382^7
 ;;^UTILITY(U,$J,358.3,4642,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4642,1,4,0)
 ;;=4^OSTEOPETROSIS
 ;;^UTILITY(U,$J,358.3,4642,1,5,0)
 ;;=5^756.52
 ;;^UTILITY(U,$J,358.3,4642,2)
 ;;=^87143
 ;;^UTILITY(U,$J,358.3,4643,0)
 ;;=579.9^^45^382^1
 ;;^UTILITY(U,$J,358.3,4643,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4643,1,4,0)
 ;;=4^MALABSORPTION SYNDROME
 ;;^UTILITY(U,$J,358.3,4643,1,5,0)
 ;;=5^579.9
 ;;^UTILITY(U,$J,358.3,4643,2)
 ;;=^123941
 ;;^UTILITY(U,$J,358.3,4644,0)
 ;;=275.40^^45^382^2
 ;;^UTILITY(U,$J,358.3,4644,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4644,1,4,0)
 ;;=4^METABOLISM D/O,CALCIUM
 ;;^UTILITY(U,$J,358.3,4644,1,5,0)
 ;;=5^275.40
 ;;^UTILITY(U,$J,358.3,4644,2)
 ;;=^18161
 ;;^UTILITY(U,$J,358.3,4645,0)
 ;;=275.2^^45^382^3
 ;;^UTILITY(U,$J,358.3,4645,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4645,1,4,0)
 ;;=4^METABOLISM D/O,MAGNESIUM
 ;;^UTILITY(U,$J,358.3,4645,1,5,0)
 ;;=5^275.2
 ;;^UTILITY(U,$J,358.3,4645,2)
 ;;=^35626
 ;;^UTILITY(U,$J,358.3,4646,0)
 ;;=275.3^^45^382^5
 ;;^UTILITY(U,$J,358.3,4646,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4646,1,4,0)
 ;;=4^METABOLISM D/O,PHOSPHORUS
 ;;^UTILITY(U,$J,358.3,4646,1,5,0)
 ;;=5^275.3
 ;;^UTILITY(U,$J,358.3,4646,2)
 ;;=^93796
 ;;^UTILITY(U,$J,358.3,4647,0)
 ;;=275.9^^45^382^4
 ;;^UTILITY(U,$J,358.3,4647,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4647,1,4,0)
 ;;=4^METABOLISM D/O,MINERAL
 ;;^UTILITY(U,$J,358.3,4647,1,5,0)
 ;;=5^275.9
 ;;^UTILITY(U,$J,358.3,4647,2)
 ;;=^267943
 ;;^UTILITY(U,$J,358.3,4648,0)
 ;;=588.0^^45^382^13
 ;;^UTILITY(U,$J,358.3,4648,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4648,1,4,0)
 ;;=4^RENAL OSTEODYSTROPHY
 ;;^UTILITY(U,$J,358.3,4648,1,5,0)
 ;;=5^588.0
 ;;^UTILITY(U,$J,358.3,4648,2)
 ;;=^104747
 ;;^UTILITY(U,$J,358.3,4649,0)
 ;;=268.9^^45^382^14
 ;;^UTILITY(U,$J,358.3,4649,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4649,1,4,0)
 ;;=4^VITAMIN D DEFICIENCY NOS
 ;;^UTILITY(U,$J,358.3,4649,1,5,0)
 ;;=5^268.9
 ;;^UTILITY(U,$J,358.3,4649,2)
 ;;=^126968
 ;;^UTILITY(U,$J,358.3,4650,0)
 ;;=251.2^^45^383^16
 ;;^UTILITY(U,$J,358.3,4650,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4650,1,4,0)
 ;;=4^HYPOGLYCEMIA NOS
 ;;^UTILITY(U,$J,358.3,4650,1,5,0)
 ;;=5^251.2
 ;;^UTILITY(U,$J,358.3,4650,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,4651,0)
 ;;=250.01^^45^383^7
 ;;^UTILITY(U,$J,358.3,4651,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4651,1,4,0)
 ;;=4^DMI w/o COMPLICATIONS
 ;;^UTILITY(U,$J,358.3,4651,1,5,0)
 ;;=5^250.01
 ;;^UTILITY(U,$J,358.3,4651,2)
 ;;=^331780
 ;;^UTILITY(U,$J,358.3,4652,0)
 ;;=250.11^^45^383^3
 ;;^UTILITY(U,$J,358.3,4652,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4652,1,4,0)
 ;;=4^DMI w/ KETOACIDOSIS
 ;;^UTILITY(U,$J,358.3,4652,1,5,0)
 ;;=5^250.11
 ;;^UTILITY(U,$J,358.3,4652,2)
 ;;=^331784
 ;;^UTILITY(U,$J,358.3,4653,0)
 ;;=250.21^^45^383^2
 ;;^UTILITY(U,$J,358.3,4653,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4653,1,4,0)
 ;;=4^DMI w/ HYPEROSMOLARITY
 ;;^UTILITY(U,$J,358.3,4653,1,5,0)
 ;;=5^250.21
 ;;^UTILITY(U,$J,358.3,4653,2)
 ;;=^331788
 ;;^UTILITY(U,$J,358.3,4654,0)
 ;;=250.41^^45^383^5
 ;;^UTILITY(U,$J,358.3,4654,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4654,1,4,0)
 ;;=4^DMI w/ RENAL COMPL
 ;;^UTILITY(U,$J,358.3,4654,1,5,0)
 ;;=5^250.41
 ;;^UTILITY(U,$J,358.3,4654,2)
 ;;=^331796
 ;;^UTILITY(U,$J,358.3,4655,0)
 ;;=250.51^^45^383^1
 ;;^UTILITY(U,$J,358.3,4655,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4655,1,4,0)
 ;;=4^DMI w/ EYE COMPL
 ;;^UTILITY(U,$J,358.3,4655,1,5,0)
 ;;=5^250.51
 ;;^UTILITY(U,$J,358.3,4655,2)
 ;;=^331800
 ;;^UTILITY(U,$J,358.3,4656,0)
 ;;=250.61^^45^383^4
 ;;^UTILITY(U,$J,358.3,4656,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4656,1,4,0)
 ;;=4^DMI w/ NEUROLOGICAL COMPL
 ;;^UTILITY(U,$J,358.3,4656,1,5,0)
 ;;=5^250.61
 ;;^UTILITY(U,$J,358.3,4656,2)
 ;;=^331804
 ;;^UTILITY(U,$J,358.3,4657,0)
 ;;=250.71^^45^383^6
 ;;^UTILITY(U,$J,358.3,4657,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4657,1,4,0)
 ;;=4^DMI w/ VASCULAR COMPL
 ;;^UTILITY(U,$J,358.3,4657,1,5,0)
 ;;=5^250.71
 ;;^UTILITY(U,$J,358.3,4657,2)
 ;;=^331808
 ;;^UTILITY(U,$J,358.3,4658,0)
 ;;=250.00^^45^383^14
 ;;^UTILITY(U,$J,358.3,4658,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4658,1,4,0)
 ;;=4^DMII w/o COMPLICATIONS
 ;;^UTILITY(U,$J,358.3,4658,1,5,0)
 ;;=5^250.00
 ;;^UTILITY(U,$J,358.3,4658,2)
 ;;=^331779
 ;;^UTILITY(U,$J,358.3,4659,0)
 ;;=250.10^^45^383^10
 ;;^UTILITY(U,$J,358.3,4659,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4659,1,4,0)
 ;;=4^DMII w/ KETOACIDOSIS
 ;;^UTILITY(U,$J,358.3,4659,1,5,0)
 ;;=5^250.10
 ;;^UTILITY(U,$J,358.3,4659,2)
 ;;=^331783
 ;;^UTILITY(U,$J,358.3,4660,0)
 ;;=250.20^^45^383^9
 ;;^UTILITY(U,$J,358.3,4660,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4660,1,4,0)
 ;;=4^DMII w/ HYPEROSMOLARITY
 ;;^UTILITY(U,$J,358.3,4660,1,5,0)
 ;;=5^250.20
 ;;^UTILITY(U,$J,358.3,4660,2)
 ;;=^331787
 ;;^UTILITY(U,$J,358.3,4661,0)
 ;;=250.40^^45^383^12
 ;;^UTILITY(U,$J,358.3,4661,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4661,1,4,0)
 ;;=4^DMII w/ RENAL COMPL
 ;;^UTILITY(U,$J,358.3,4661,1,5,0)
 ;;=5^250.40
 ;;^UTILITY(U,$J,358.3,4661,2)
 ;;=^331795
 ;;^UTILITY(U,$J,358.3,4662,0)
 ;;=250.50^^45^383^8
 ;;^UTILITY(U,$J,358.3,4662,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4662,1,4,0)
 ;;=4^DMII w/ EYE COMPL
 ;;^UTILITY(U,$J,358.3,4662,1,5,0)
 ;;=5^250.50
 ;;^UTILITY(U,$J,358.3,4662,2)
 ;;=^331799
 ;;^UTILITY(U,$J,358.3,4663,0)
 ;;=250.60^^45^383^11
 ;;^UTILITY(U,$J,358.3,4663,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4663,1,4,0)
 ;;=4^DMII w/ NEUROLOGICAL COMPL
 ;;^UTILITY(U,$J,358.3,4663,1,5,0)
 ;;=5^250.60
 ;;^UTILITY(U,$J,358.3,4663,2)
 ;;=^331803
 ;;^UTILITY(U,$J,358.3,4664,0)
 ;;=250.70^^45^383^13
 ;;^UTILITY(U,$J,358.3,4664,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4664,1,4,0)
 ;;=4^DMII w/ VASCULAR COMPL
 ;;^UTILITY(U,$J,358.3,4664,1,5,0)
 ;;=5^250.70
 ;;^UTILITY(U,$J,358.3,4664,2)
 ;;=^331807
 ;;^UTILITY(U,$J,358.3,4665,0)
 ;;=272.0^^45^384^4
 ;;^UTILITY(U,$J,358.3,4665,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4665,1,4,0)
 ;;=4^PURE HYPERCHOLESTEROLEM
 ;;^UTILITY(U,$J,358.3,4665,1,5,0)
 ;;=5^272.0
 ;;^UTILITY(U,$J,358.3,4665,2)
 ;;=^59973
 ;;^UTILITY(U,$J,358.3,4666,0)
 ;;=272.1^^45^384^5
 ;;^UTILITY(U,$J,358.3,4666,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4666,1,4,0)
 ;;=4^PURE HYPERGLYCERIDEMIA
 ;;^UTILITY(U,$J,358.3,4666,1,5,0)
 ;;=5^272.1
 ;;^UTILITY(U,$J,358.3,4666,2)
 ;;=^101303
 ;;^UTILITY(U,$J,358.3,4667,0)
 ;;=272.2^^45^384^3
 ;;^UTILITY(U,$J,358.3,4667,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4667,1,4,0)
 ;;=4^MIXED HYPERLIPIDEMIA
 ;;^UTILITY(U,$J,358.3,4667,1,5,0)
 ;;=5^272.2
 ;;^UTILITY(U,$J,358.3,4667,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,4668,0)
 ;;=272.4^^45^384^1
 ;;^UTILITY(U,$J,358.3,4668,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4668,1,4,0)
 ;;=4^HYPERLIPIDEMIA NEC/NOS
 ;;^UTILITY(U,$J,358.3,4668,1,5,0)
 ;;=5^272.4
 ;;^UTILITY(U,$J,358.3,4668,2)
 ;;=^87281
 ;;^UTILITY(U,$J,358.3,4669,0)
 ;;=272.6^^45^384^2
 ;;^UTILITY(U,$J,358.3,4669,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4669,1,4,0)
 ;;=4^LIPODYSTROPHY
 ;;^UTILITY(U,$J,358.3,4669,1,5,0)
 ;;=5^272.6
 ;;^UTILITY(U,$J,358.3,4669,2)
 ;;=^71106
 ;;^UTILITY(U,$J,358.3,4670,0)
 ;;=253.0^^45^385^1
 ;;^UTILITY(U,$J,358.3,4670,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4670,1,4,0)
 ;;=4^ACROMEGALY AND GIGANTISM
 ;;^UTILITY(U,$J,358.3,4670,1,5,0)
 ;;=5^253.0
 ;;^UTILITY(U,$J,358.3,4670,2)
 ;;=^2351
 ;;^UTILITY(U,$J,358.3,4671,0)
 ;;=255.0^^45^385^2
 ;;^UTILITY(U,$J,358.3,4671,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4671,1,4,0)
 ;;=4^CUSHING'S SYNDROME
 ;;^UTILITY(U,$J,358.3,4671,1,5,0)
 ;;=5^255.0
 ;;^UTILITY(U,$J,358.3,4671,2)
 ;;=^29802
 ;;^UTILITY(U,$J,358.3,4672,0)
 ;;=253.5^^45^385^3
 ;;^UTILITY(U,$J,358.3,4672,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4672,1,4,0)
 ;;=4^DIABETES INSIPIDUS
 ;;^UTILITY(U,$J,358.3,4672,1,5,0)
 ;;=5^253.5
 ;;^UTILITY(U,$J,358.3,4672,2)
 ;;=^33572
 ;;^UTILITY(U,$J,358.3,4673,0)
 ;;=253.8^^45^385^4
 ;;^UTILITY(U,$J,358.3,4673,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4673,1,4,0)
 ;;=4^EMPTY SELLA SYNDROME
 ;;^UTILITY(U,$J,358.3,4673,1,5,0)
 ;;=5^253.8
 ;;^UTILITY(U,$J,358.3,4673,2)
 ;;=^87533
 ;;^UTILITY(U,$J,358.3,4674,0)
 ;;=253.1^^45^385^5
 ;;^UTILITY(U,$J,358.3,4674,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4674,1,4,0)
 ;;=4^HYPERPROLACTINEMIA
 ;;^UTILITY(U,$J,358.3,4674,1,5,0)
 ;;=5^253.1
 ;;^UTILITY(U,$J,358.3,4674,2)
 ;;=^87260
 ;;^UTILITY(U,$J,358.3,4675,0)
 ;;=253.2^^45^385^6
 ;;^UTILITY(U,$J,358.3,4675,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4675,1,4,0)
 ;;=4^PANHYPOPITUITARISM
 ;;^UTILITY(U,$J,358.3,4675,1,5,0)
 ;;=5^253.2
 ;;^UTILITY(U,$J,358.3,4675,2)
 ;;=^60686
 ;;^UTILITY(U,$J,358.3,4676,0)
 ;;=227.3^^45^385^7
 ;;^UTILITY(U,$J,358.3,4676,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4676,1,4,0)
 ;;=4^PITUITARY TUMOR,BENIGN
 ;;^UTILITY(U,$J,358.3,4676,1,5,0)
 ;;=5^227.3
 ;;^UTILITY(U,$J,358.3,4676,2)
 ;;=^267690
 ;;^UTILITY(U,$J,358.3,4677,0)
 ;;=253.8^^45^385^8
 ;;^UTILITY(U,$J,358.3,4677,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4677,1,4,0)
 ;;=4^RATHKE'S CYST
 ;;^UTILITY(U,$J,358.3,4677,1,5,0)
 ;;=5^253.8
 ;;^UTILITY(U,$J,358.3,4677,2)
 ;;=^87533
 ;;^UTILITY(U,$J,358.3,4678,0)
 ;;=253.4^^45^386^3
 ;;^UTILITY(U,$J,358.3,4678,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4678,1,4,0)
 ;;=4^ANTER PITUITARY DIS NEC
 ;;^UTILITY(U,$J,358.3,4678,1,5,0)
 ;;=5^253.4
 ;;^UTILITY(U,$J,358.3,4678,2)
 ;;=^267862
 ;;^UTILITY(U,$J,358.3,4679,0)
 ;;=258.9^^45^386^14
 ;;^UTILITY(U,$J,358.3,4679,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4679,1,4,0)
 ;;=4^POLYGLANDUL DYSFUNC NOS
 ;;^UTILITY(U,$J,358.3,4679,1,5,0)
 ;;=5^258.9
 ;;^UTILITY(U,$J,358.3,4679,2)
 ;;=^267894
